POM-V Prescription Required Companion Animal

Vominil 10 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Maropitant

Form

Injection

Species

Cats Dogs

Manufacturer

VetViva Richter GmbH

VMD MA No.

57446/3004

What it's used for

Cats • induced by motion sickness. •

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Maropitant

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Vominil 10 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Cats
•
induced by motion sickness.
•

The veterinary medicinal product should be injected subcutaneously or intravenously,
once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight) for up to 5
consecutive days. Intravenous administration of the veterinary medicinal product
should be given as a single bolus without mixing the veterinary medicinal product
with any other fluids.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
To prevent vomiting, the veterinary medicinal product should be administered more
than 1 hour in advance. The duration of effect is approximately 24 h and therefore
treatment can be given the night before administration of an agent that may cause
emesis e.g. chemotherapy.
As the pharmacokinetic variation is large and maropitant accumulates in the body
after once daily repeated administration, lower doses than recommended might be
sufficient in some individuals and when repeating the dose.
For administration by subcutaneous injection, see also ‘special precautions for safe
use in the target species’ (section 3.5).
The rubber stopper may be safely punctured up to 100 times.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Dogs and cats:
Very common
(>1 animal / 10 animals
treated):
Injection site pain*Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactic-type reaction, allergic oedema,
urticaria, erythema, collapse, dyspnoea, pale
mucous membrane;
Lethargy;
Neurological disorders (e.g. ataxia,
convulsion/seizure, muscle tremor)
*May occur when injected subcutaneously. In approximately one third of cats
moderate to severe response to injection is observed.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also section ‘contact
details’ of the package leaflet for respective contact details.

Vomiting can be associated with serious, severely debilitating conditions including
gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be
employed.
Good veterinary practice indicates that antiemetics should be used in conjunction
with other veterinary and supportive measures such as dietary control and fluid
replacement therapy while addressing the underlying causes of the vomiting.
The use of the veterinary medicinal product against vomiting due to motion sickness
is not recommended.
Dogs:
Although maropitant has been demonstrated to be effective in both the treatment and
prevention of emesis induced by chemotherapy, it was found more efficacious if used
preventively. Therefore, it is recommended to administer the antiemetic prior to
administration of the chemotherapeutic agent.
Cats:
The efficacy of maropitant in reduction of nausea was demonstrated in studies using
a model (xylazine-induced nausea).

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in dogs less
than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or
lactating dogs and cats. Use only according to the benefit-risk assessment by the
responsible veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution in
patients with hepatic disease. As maropitant is accumulated in the body during a 14-
day treatment period due to metabolic saturation, careful monitoring of liver function
and any adverse events should be implemented during long term treatment.
The veterinary medicinal product should be used with caution in animals suffering
from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and
K-ion channels. Increases of approximately 10% in the QT interval of the ECG were
observed in a study on healthy beagle dogs administered 8 mg/kg orally; however,
such an increase is unlikely to be of clinical significance.
Due to the frequent occurrence of transient pain during subcutaneous injection,
appropriate animal restraining measures may have to be applied. Injecting the
veterinary medicinal product at refrigerated temperature may reduce pain at injection.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
This product may cause skin sensitisation. People with known hypersensitivity to
maropitant should administer the veterinary medicinal product with caution. Wash the
exposed skin immediately after exposure with large amounts of water. If you develop
symptoms such as a rash after accidental exposure, seek medical advice and show
the physician this warning.
This veterinary medicinal product may be irritant to the eyes. Avoid eye contact. In
case of accidental contact of the product with eyes rinse abundantly with fresh water.
If symptoms occur, seek the advice of a physician.
Maropitant is a neurokinin-1 (NK1) receptor antagonist that acts in the central
nervous system. Accidental self-injection or ingestion may result in nausea, dizziness
and somnolence. Care should be taken to avoid accidental self-injection. In case of
accidental oral intake or self-injection seek medical advice immediately and show the
package leaflet or the label to the physician.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

The veterinary medicinal product should not be used concomitantly with Ca-channel
antagonists as maropitant has affinity to Ca-channels.
Maropitant is highly bound to plasma proteins and may compete with other highly
bound medicines.

Do not freeze.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.